martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Burry's broader argument about semiconductor stocks, especially Micron, is not entirely wrong; memory and momentum chip stocks are priced as if nothing can go wrong

    60% confidence
  • Custom-ASIC HBM demand will grow 82% in 2026, a third of the total HBM market

    60% confidence
  • Burry's worry deserves respect; hyperscalers may be overbuilding and some AI computing could become a cheap commodity

    60% confidence
  • A DCF model puts Micron's fair value at $1,527.88, more than 50% above the then-current price, leaning on the Anthropic partnership and the $250 billion US manufacturing buildout

    60% confidence
  • Micron is becoming an 'infrastructure toll-bridge' rather than a cyclical chipmaker, and the stock should re-rate from its current forward multiple toward an infrastructure-like 16-19.5x

    60% confidence
  • Micron is cyclical like no other; the stock's rally reached historically extreme levels driven by FOMO and greater fool theory, not fundamentals, and AI chip stocks face a 30% correction

    60% confidence
  • Micron doesn't need to beat SK hynix at supplying Nvidia; it just needs to hold its roughly 21-22% HBM revenue share as hyperscalers build custom AI chips needing HBM independent of Nvidia's GPU cycle

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com